Randomised Trial of Genetic Testing and Targeted Zoledronic acid Therapy to Prevent SQSTM1 Mediated Paget’s Disease
Zoledronate in the Prevention of Paget's
The main aim of the study is to determine if targeted intervention with Zoledronic acid can prevent the development of Paget’s disease of bone (PDB) in subjects who are genetically predisposed to PDB.
Chief Investigator: Professor Stuart Ralston
Number and location of participating sites (by region/ country): This is an international randomised controlled trial with centres in UK, Australia, New Zealand, Spain, Italy, Belgium, and Ireland.
EudraCT number: 2008-005667-34
ISRCTN number: ISRCTN11616770 http://www.controlled-trials.com/ISRCTN11616770
Funder: MRC, Arthritis Research UK
Start and End date
Of grant award: 9 July 2008 - 31 May 2021
Current Status: Closed to recruitment.
Trial Unblinding Information: Please refer to the study protocol.
UK GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with UK GDPR, please read this document.
For any enquiries regarding this trial please contact the ZiPP trial office by email (firstname.lastname@example.org) or on tel: 0131 651 9917.
ECTU Involvement: Trial Manager, Statistics and Database, Research Nurses